Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Holding(s) in Company

5th Dec 2007 12:00

Basingstoke, UK and Philadelphia, US - December 05, 2007 - Shire plc

Notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights

Other (please specify): New Exemption DTR 5.1.3 (4) & DTR 5.1.5 Yes (1)

3. Full name of person(s) subject to the notification obligation: The Goldman Sachs Group Inc 4. Full name of shareholder(s) (if different from 3.): Goldman, Sachs & Co.

5. Date of the transaction (and date on which the threshold is 30 November crossed

2007 or reached if different): 6. Date on which issuer notified: 04 December 2007 7. Threshold(s) that is/are crossed or reached: 3% 8. Notified details:

A: Voting rights attached to shares

Class/type of Situation Resulting situation after the triggering shares previous to transaction if possible the Triggering using the ISIN transaction CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Direct Indirect Direct Indirect GB00B0KQX869 Below 3% 1,929,050 0.35% US82481R1068 Below 3% 15,656,661 2.80% (5,218,887ADRs) B: Financial Instruments

Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of financial date Conversion rights that may be voting instrument Period/ Date acquired if the rights instrument is exercised/converted Total (A+B) Number of voting rights % of voting rights 17,585,711 3.15%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

The interest in 1,929,050 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers. These shares are, or will be, registered in the name of Goldman Sachs Securities (Nominees), Limited.

The interest in 15,610,758 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as custodian for its customers of 5,203,586 American Depositary Receipts ("ADRs"). These ADRs are, or will be, held at the Depositary Trust Company of New York ("DTC").

The interest in 45,903 shares arose from an interest held by Goldman, Sachs & Co., a wholly-owned direct subsidiary of GS Inc, acting as discretionary manager of 15,301 American Depositary Receipts ("ADRs"). These ADRs are, or will be, held at the Depositary Trust Company of New York ("DTC").

Proxy Voting:10. Name of the proxy holder: N/A

11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting N/A

rights: 13. Additional information: General Email Contact: [email protected] 14. Contact name: Sean Rogers/Alex Cox

15. Contact telephone number: 44(20)7552-9205/ 44(20)774-8774

(Contact at Shire plc: Phil Griffin-Smith, Interim Deputy Company Secretary, 01256 894754)

For further information please contact:

Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: www.shire.com.

Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release

Registered in England 5492592Registered Office as above

SHIRE PLC

Related Shares:

Shire
FTSE 100 Latest
Value8,774.65
Change-17.15